<DOC>
	<DOCNO>NCT00039832</DOCNO>
	<brief_summary>This study evaluate safety effectiveness two type blood thinner , abciximab ( ReoPro ) reteplase ( Retavase ) restore normal brain blood flow ischemic stroke ( stroke result blood clot brain ) . The therapy approve Food Drug Administration treat ischemic stroke clot buster drug rt-PA . This treatment , however , effective begin within 3 hour onset stroke patient get hospital early enough benefit . There thus press need develop effective stroke treatment initiate 3 hour onset . Patients 18 80 year age experience mild moderate acute stroke 3 24 hour start study drug may eligible study . Candidates screen physical examination , blood test magnetic resonance imaging ( MRI ) scan ( MRI do stroke evaluation ) . All participant receive ReoPro . Some also receive Retavase , may boost effectiveness ReoPro . Retavase administer single dose needle vein 2 minute . ReoPro infuse vein 12 hour . Patients monitor physical examination , blood test , compute tomography ( CT ) scan , three four MRI scan brain evaluate response treatment side effect drug . An MRI scan do 24 hour , 5 day 30 day start study medication , possibly screen study . CT involve use specialized x-ray obtain image brain . The patient lie still scanner short time X-ray image form . MRI use strong magnetic field radio wave demonstrate structural chemical change tissue . MRI sensitive x-ray evaluate acute stroke . The patient lie table metal cylinder ( scanner ) picture take . During part MRI , medicine call gadolinium contrast inject vein . This medicine brighten image , create good picture blood flow .</brief_summary>
	<brief_title>ReoPro Retavase Restore Brain Blood Flow After Stroke</brief_title>
	<detailed_description>Objectives : This clinical trial determine acceptable dose reteplase combination fix dose abciximab ischemic stroke 3-24 hour onset . Study Population : Patients select criterion minimize likelihood toxicity maximize likelihood response . These criterion include age 18-80 year old , acute ischemic stroke moderate severity ( NIH Stroke Scale less equal 16 lesion volume diffusion MRI less approximately one third volume middle cerebral artery territory ) , positive MRI evidence hypoperfusion correspond acute stroke symptom , MRI evidence chronic micro-hemorrhages , clinical , radiological laboratory feature associate risk hemorrhage thrombolytic therapy . Design : The study open-label , dose escalation , safety proof principle study combination intravenous abciximab reteplase . A fixed dose abciximab use patient : 0.25 mg/kg bolus ( maximum 30 mg ) follow 0.125 microgram/kg/minute infusion ( maximum 10.0 microgram/minute ) 12 hour . The five dose group reteplase dose 0 U , 2.5 U , 5.0 U , 7.5 U , 10.0 U . A maximum 72 patient treat use adaptive statistical design , data response toxicity use determine dose subsequent patient , thereby minimize exposure either ineffective toxic dos . Non-investigational patient management standardize across patient accord NIH Stroke Center Clinical Care Pathway . Outcome Measures : The primary efficacy endpoint response reperfusion MRI 24 hour start therapy . The primary safety endpoint determination toxicity one following : symptomatic intracranial hemorrhage ( ICH ) , major systemic hemorrhage , serious adverse event relate study drug administration , include death , within 48 hour start therapy . The maximum acceptable rate toxicity 10 % patient treat dose level minimum acceptable rate response 50 % patient treat dose level . The outcome monitor Data Safety Monitoring Committee , authority stop recommend modification trial safety concern . Other clinical outcome variable image variable record analyzed secondary exploratory analysis . If acceptable dose identify , investigated subsequent randomize placebo-controlled trial .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Reteplase</mesh_term>
	<criteria>INCLUSION CRITERIA : Patients may enrol study meet follow criterion : 1 . Diagnosis acute ischemic stroke onset 3 24 hour prior plan start study drug . Acute ischemic stroke define measurable neurological deficit sudden onset , presume secondary focal cerebral ischemia , otherwise attributable ICH another disease process . Stroke onset defined time patient last know without new clinical deficit . Patients whose deficit worsen last 24 hour eligible first symptom start 24 hour . If stroke start sleep , stroke onset recorded time patient last know intact . A careful history important determine patient last without present deficit . 2 . Disabling neurological deficit attributable acute stroke start study drug . 3 . NIHSS le equal 16 . 4 . Evidence PWI MRI perfusion defect correspond acute stroke syndrome least 2cm diameter long short axis slice . The PWI assess relative mean transit time ( MTT ) image . The MRI evaluation must involve echo planar diffusion weight imaging , MRA , MRI perfusion . A normal appear MRA appropriate perfusion defect eligible . An apparent stenosis occlusion MRA normal appear perfusion distally eligible . Poor quality uninterpretable MRA make patient ineligible . Patients normal DWI eligible . 5 . Age 18 80 year , inclusive . EXCLUSION CRITERIA : Patients exclude study follow reason : General : 1 . Current participation another study investigational drug device within , prior participation present study , plan participation another therapeutic trial , prior final assessment trial . 2 . Time interval since stroke onset le 24 hour impossible determine high degree confidence . 3 . Symptoms suggestive subarachnoid hemorrhage , even CT MRI scan negative hemorrhage . 4 . Evidence acute myocardial infarction define least two follow three feature : 1 . ) Chest pain suggestive cardiac ischemia ; 2 . ) EKG finding ST elevation great 0.2 mV 2 contiguous lead , new onset leave bundle branch block , ST segment depression , Twave inversion ; 3 . ) Elevated troponin I 5 . Contraindication MRI scan . 6 . Women know pregnant , lactate positive indeterminate pregnancy test . 7 . Patients would refuse blood transfusion medically indicate . Stroke Related : 8 . Neurological deficit lead stupor coma ( NIHSS level consciousness score great equal 2 ) . 9 . High clinical suspicion septic embolus . 10 . Minor stroke nondisabling deficit rapidly improve neurological symptom . 11 . Baseline NIHSS great 16 . MRI/CT Related : 12 . Evidence acute chronic ICH head CT MRI . 13 . Evidence microbleed gradient echo MRI ( GRE ) . 14 . CT MRI evidence nonvascular cause neurological symptom . 15 . Signs mass effect cause shift midline structure . 16 . Incomplete uninterpretable DWI PWI . 17 . DWI abnormality large approximately one third territory middle cerebral artery territory qualitative assessment . 18 . Satellite DWI hyperintensity correspond hyperintensity T2 weight image FLAIR vascular territory different index stroke ( evidence new ischemic lesion possibly great 24 hour duration ) . Safety Related : 19 . Persistent hypertension systolic BP great 185 mmHg diastolic BP great 110 mmHg ( mean 3 consecutive arm cuff reading 2030 minute ) , control antihypertensive therapy require nitroprusside control . 20 . Anticipated need major surgery within 72 hour start study drug , e.g. , carotid endarterectomy , hip fracture repair . 21 . Any intracranial surgery , serious head trauma ( head injury require hospitalization ) , within past 3 month . 22 . Stroke within past 3 month . 23 . History ICH time past . 24 . Major trauma time stroke , e.g. , hip fracture . 25 . Blood glucose great 200 mg/dl . 26 . Presence history intracranial neoplasm ( except small meningioma ) arteriovenous malformation . 27 . Intracranial aneurysm , unless surgically treat great 3 month . 28 . Major hemorrhage past 21 day . 29 . Major surgery , serious trauma , lumbar puncture , arterial puncture noncompressible site , biopsy parenchymal organ last 14 day . Major surgical procedure include limited following : major thoracic abdominopelvic surgery , neurosurgery , major limb surgery , carotid endarterectomy vascular surgery , organ transplant . For nonlisted procedure , operate surgeon consult assess risk . 30 . Presumed documented history vasculitis . 31 . Known systemic bleeding disorder , e.g. , von Willebrand 's disease , hemophilia , others . 32 . Platelet count le 100,000 cells/microL . 33 . Congenital acquire coagulopathy ( e.g . secondary anticoagulant cause either follow : 1 . Activated partial thromboplastin time ( aPPT ) prolongation great 2 second upper limit normal local laboratory , except due isolated factor XII deficiency . Protamine sulfate reversal heparin effect alleviate criterion . 2 . INR great equal 1.4 . Patients receive warfarin prior entry eligible provide INR le 1.4 warfarin safely discontinue least 48 hour . Potentially Interfering Outcome Assessment : 34 . Life expectancy le 3 month . 35 . Other serious illness , e.g. , severe hepatic , cardiac , renal failure ; acute myocardial infarction ; complex disease may confound treatment assessment . 36 . Serum creatinine , AST ALT great 3 time upper limit normal local laboratory . Drug Related : 37 . Treatment qualify stroke thrombolytic GPIIbIIIa inhibitor outside protocol . 38 . Any administration thrombolytic drug prior 7 day . 39 . Treatment qualify stroke intravenous heparin unless aPTT prolongation great 2 second upper limit normal local laboratory prior study drug initiation . 40 . Treatment qualify stroke low molecular weight heparinoid . 41 . Previous administration abciximab , know . 42 . Known allergy murine protein . 43 . Anticoagulation ( evidenced PT , PTT , platelet count ) cause herbal therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Stroke</keyword>
	<keyword>Abciximab</keyword>
	<keyword>Reteplase</keyword>
	<keyword>MRI</keyword>
	<keyword>Cerebral Blood Flow</keyword>
</DOC>